Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daiichi Sankyo Goes After Generics In Japan, Forms New Company With Ranbaxy

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - As Teva and Mylan drill deeper into the steadily unfolding Japanese generic drugs market, Daiichi Sankyo - the third largest Japanese drug maker - does not want to be left behind
Advertisement

Related Content

After Years Of Partner Search, India's Dr. Reddy's Forms JV With Fujifilm To Tap Japanese Generics Market
After Years Of Partner Search, India's Dr. Reddy's Forms JV With Fujifilm To Tap Japanese Generics Market
Daiichi Sankyo Rolls Out Generics In Japan While Ranbaxy Products Still On Hold In U.S.
Sanofi-Aventis Reportedly In Talks With Nichi-Iko, Could Make Big Splash In Biosimilars
Ranbaxy Outperforms Behind Generic Valtrex, But FDA Corrective Action Looms
New Approaches To Innovation Needed To Reach Globe's Poor At The "Bottom Of The Pyramid" - And To Fend Off Emerging Competitors Around The World
US-India Healthcare Summit: New Business Models Needed To Reach the World's Poor
Daiichi Sankyo Generics Entry Could Help Japan's Branded Generics Makers
Teva-Kowa To Commence Marketing Generics In Japan In January
Teva-Kowa To Commence Marketing Generics In Japan In January
Advertisement
UsernamePublicRestriction

Register

SC074144

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel